|
| An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
|
Pharmacological Action Antiparkinson Agents; Dopamine Agents; Enzyme Inhibitors | Other names Seryltrihydroxybenzylhydrazine; Serazide; Ro 44602; Ro 4 4602; Benzylhydrazine, Seryltrihydroxy; Seryltrihydroxy Benzylhydrazine; Ro 4-4602; DL-Serine 2-((2,3,4-trihydroxyphenyl)methyl)hydraz; Seryltrihydroxybenzylhydrazine; Serazide
| |
| Substance | CAS Registry & name | Categories | Source | Drugs*
|
| madopar
| 37270-69-2
|
*Benserazide *Levodopa Drug Combinations Dopa Decarboxylase/antagonists & inhibitors.
Pharma Action Enzyme Inhibitors ; Dopamine Agents
|
Acta Neurol 28(2):208;1973; Acta Neurol Scand 53(3):189;1976; Br Med J 1(5957):573;1975; Wien Med Wochenschr 123(26):433;1973
|
| |
| |